An article in Nature Genetics reports how SMARCB1 protein deficiency triggers a series of events, resulting in rhabdoid tumor -- a malignant rumor that has no defined standard of care. If you need SMARCB1 protein or Recombinant NTRK3, CusAb is a good supplier. Rhabdoid tumor usually starts to cause symptoms in early life. It arises in various tissues of the body, such as the kidney, liver, lung, heart and the nervous system. Its survival rate is as low as 20-25%. Efficacious therapeutics are in urgent need. Using genome sequencing technique, scientists have so far identified large numbers of mutations in diverse cancers, improving the understanding of how a cancer forms, develops, and becomes resistant to treatment. However, rhabdoid tumor is genetically stable, meaning that it has less mutations in comparison to many other types of cancer. Dana-Farber Cancer Institute, Boston Children's Hospital, Harvard Medical School, Massachusetts General Hospital collaborate with other institutes to investigate why rhabdoid tumor is so almost untreatable. Given that habdoid tumor cells frequently contain deletion of SMARCB1 protein, the researchers focused on this protein and showed how SMARCB1 deficiency can impair the function of a tumor suppressor, allowing for the rapid growth of rhabdoid tumor cells. SMARCB1 protein is a member of the SWI/SNF complex. This complex functions to regulate gene transcription and DNA repair. Some studies have found SWI/SNF to be a tumor suppressor. The researchers then performed an analysis of rhabdoid tumor tissues from human patients. They found that SMARCB1 loss greatly decreased the amounts of other subunits of the SWI/SNF complex, seriously affecting the SWI/SNF complex's regulatory ability in gene expression. SMARCB1 deficiency may activate the genes that cancer cells need to replicate and survive, the researchers suspected. Restoration of SMARCB1 in rhabdoid tumor cells halted cell growth, the study found. Since many other human cancers also contain mutations in the SWI/SNF complex. So the findings may also move to other cancers.
